if they could work out a win/win (at least appear so) then why not,an agreement where a tacit t-enox delay in fda response and and agreement not to launch mcopax for a year if approved in 2011/2012etc..,with t-enox overhang MNTA doubles overnight based just on $5 cash per share and $4 earnings per year, teva gets copax breathing room and mnta gets lovenox breathing room.
regulatory work arounds couldbe difficult but a deal around the patents may work, assuming momenta believe teva's lovenox is a real threat and that novartis would go along with it.
Market Data 
Markets 
AI
